江西医药
江西醫藥
강서의약
JIANGXI MEDICAL JOURNAL
2014年
12期
1345-1348
,共4页
田莉峰%伍琼芳%李游%苏琼%许定飞%黎梦溪
田莉峰%伍瓊芳%李遊%囌瓊%許定飛%黎夢溪
전리봉%오경방%리유%소경%허정비%려몽계
多囊卵巢综合征%GnRH拮抗剂%GnRH激动剂%体外受精-胚胎移植%卵巢过度刺激综合征
多囊卵巢綜閤徵%GnRH拮抗劑%GnRH激動劑%體外受精-胚胎移植%卵巢過度刺激綜閤徵
다낭란소종합정%GnRH길항제%GnRH격동제%체외수정-배태이식%란소과도자격종합정
PCOS%GnRH Antagonist Protocols%GnRH Agonist Protocols%In Vitro Fertilization-Embryo Transfer%OHSS
目的:探讨促性腺激素释放激素拮抗剂(GnRH-ant)方案在多囊卵巢综合症(polycystic ovary syndrome,PCOS)患者行体外受精-胚胎移植(In Vitro Fertilization-Embryo Transfer,IVF-ET)治疗中的应用。方法将2013年6月至2014年4月在我中心行IVF/ICSI助孕治疗的141例PCOS患者随机分为两组:GnRH拮抗剂组62例和GnRH激动剂长方案组(对照组)79例,比较两组的基线水平、临床结局及并发症等指标。结果两组患者的基线水平指标相比均无统计学差异(P>0.05)。两组获卵数、2PN受精率、卵裂率、移植胚胎数、HCG日内膜厚度、HCG日E2及P水平、临床妊娠率、种植率比较均无明显差异(P>0.05);拮抗剂组Gn总量及天数均少于对照组(P<0.05);拮抗剂组优胚率比对照组高(P<0.05);拮抗剂组HCG日LH的水平高于对照组(P<0.05),差异有统计学意义。拮抗剂组中、重度OHSS发生率与对照组比较差异无统计学意义。结论拮抗剂方案较激动剂方案能降低OHSS发生风险,而获卵数、受精率、卵裂率、种植率、临床妊娠率方面不受影响;拮抗剂方案能缩短治疗周期、降低治疗费用,具有较好的有效性和安全性,对PCOS患者行是一种比较理想的选择。
目的:探討促性腺激素釋放激素拮抗劑(GnRH-ant)方案在多囊卵巢綜閤癥(polycystic ovary syndrome,PCOS)患者行體外受精-胚胎移植(In Vitro Fertilization-Embryo Transfer,IVF-ET)治療中的應用。方法將2013年6月至2014年4月在我中心行IVF/ICSI助孕治療的141例PCOS患者隨機分為兩組:GnRH拮抗劑組62例和GnRH激動劑長方案組(對照組)79例,比較兩組的基線水平、臨床結跼及併髮癥等指標。結果兩組患者的基線水平指標相比均無統計學差異(P>0.05)。兩組穫卵數、2PN受精率、卵裂率、移植胚胎數、HCG日內膜厚度、HCG日E2及P水平、臨床妊娠率、種植率比較均無明顯差異(P>0.05);拮抗劑組Gn總量及天數均少于對照組(P<0.05);拮抗劑組優胚率比對照組高(P<0.05);拮抗劑組HCG日LH的水平高于對照組(P<0.05),差異有統計學意義。拮抗劑組中、重度OHSS髮生率與對照組比較差異無統計學意義。結論拮抗劑方案較激動劑方案能降低OHSS髮生風險,而穫卵數、受精率、卵裂率、種植率、臨床妊娠率方麵不受影響;拮抗劑方案能縮短治療週期、降低治療費用,具有較好的有效性和安全性,對PCOS患者行是一種比較理想的選擇。
목적:탐토촉성선격소석방격소길항제(GnRH-ant)방안재다낭란소종합증(polycystic ovary syndrome,PCOS)환자행체외수정-배태이식(In Vitro Fertilization-Embryo Transfer,IVF-ET)치료중적응용。방법장2013년6월지2014년4월재아중심행IVF/ICSI조잉치료적141례PCOS환자수궤분위량조:GnRH길항제조62례화GnRH격동제장방안조(대조조)79례,비교량조적기선수평、림상결국급병발증등지표。결과량조환자적기선수평지표상비균무통계학차이(P>0.05)。량조획란수、2PN수정솔、란렬솔、이식배태수、HCG일내막후도、HCG일E2급P수평、림상임신솔、충식솔비교균무명현차이(P>0.05);길항제조Gn총량급천수균소우대조조(P<0.05);길항제조우배솔비대조조고(P<0.05);길항제조HCG일LH적수평고우대조조(P<0.05),차이유통계학의의。길항제조중、중도OHSS발생솔여대조조비교차이무통계학의의。결론길항제방안교격동제방안능강저OHSS발생풍험,이획란수、수정솔、란렬솔、충식솔、림상임신솔방면불수영향;길항제방안능축단치료주기、강저치료비용,구유교호적유효성화안전성,대PCOS환자행시일충비교이상적선택。
Objective To discuss the application of GnRH antagonist protocol in vitro fertilization-embryo transfer (IVF-ET) in PCOS patients. Methods 141 PCOS patients who undergoing IVF/ICSI treatment in our center from June 2013 to April 2014 were randomly divided into two groups:62 patients who underwent GnRH antagonist protocol and 79 patients who underwent long GnRH agonist protocol (control group). The baseline,clinical outcomes and complications were compared between the two groups. Results The baselines of two groups compared were not statistically different (P>0.05). There were no significant difference of re-trieved oocytes,2PN fertilization rate,cleavage rate,numbers of embryo transferred,endometrial thickness,serum E2 and P value on the day of HCG administration,clinical pregnancy rate and implantation rate between the two groups (P>0.05). The total dose and stimulation time of gonadotropin in antagonist group were less than the control group (P<0.05);the high qualified embryo rate was higher in GnRH antagonist protocol (P<0.05);serum LH level on the day of HCG administration in antagonist protocol was higher (P<0.05). The incidence of moderate and severe OHSS in antagonist protocol was less than the control group,but the differ-ence was not statistically significance (P>0.05). Conclusion Compared with the GnRH agonist protocol,the GnRH antagonist pro-tocol can reduce the incidence of moderate and severe ovarian hyperstimulation syndrome,and has the same effect in retrieving oocytes,2PN fertilization rate,cleavage rate,implantation rate,and clinical pregnancy rate. Because the GnRH antagonist can de-crease the treatment duration and cost,and has better safety,so it may be an ideal choice for PCOS patients to have IVF-ET thera-py.